Porous shells - inspired by sea urchins - help defend biomacromolecules from the outside world.

Engineered E. coli colonies could be trump cards in the war against drug resistance.

The first US biosimilar - Zarxio from Sandoz - has been cleared for market. But the judges say it wasn't an easy decision.

After 28 years of R&D at GSK, the world has its first malaria vaccine.

A new mathematical model aims to improve drugs for cancer, viruses and bacteria.

A round-up of the latest expansion plans and new facilities as building fever grips the industry

Could existing drugs be repurposed as a shortcut to treating Ebola?

Big pharma is turning to outside sources to fill pipelines, but how often are companies backing the wrong horse?

Manufacturers must prove that new drug products are free of cancer-causing impurities

How did the NIH get it so wrong – and how can it move on?